A5100683751- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- RNA modifications and cancer
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Treatment and Pharmacology
- Metastasis and carcinoma case studies
- Cytokine Signaling Pathways and Interactions
- Brain Metastases and Treatment
- Genomics, phytochemicals, and oxidative stress
- Gastrointestinal Tumor Research and Treatment
- Genetic factors in colorectal cancer
- PI3K/AKT/mTOR signaling in cancer
- Peptidase Inhibition and Analysis
- Glutathione Transferases and Polymorphisms
- Radiomics and Machine Learning in Medical Imaging
- Biochemical and Molecular Research
- Synthesis and biological activity
- Cancer-related Molecular Pathways
Zhejiang Cancer Hospital
2016-2025
Beijing Hospital
2025
Beijing Geriatric Hospital
2025
China United Network Communications Group (China)
2024
Cancer Hospital of Chinese Academy of Medical Sciences
2020-2023
University of Chinese Academy of Sciences
2020-2023
Chinese Academy of Sciences
2020-2023
Nuclear and Radiation Safety Center
2023
Université Paris-Saclay
2023
Institut Gustave Roussy
2023
Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that selective for EGFR-TKI-sensitizing and
Ensartinib, an oral tyrosine kinase inhibitor of anaplastic lymphoma (ALK), has shown systemic and central nervous system efficacy for patients with ALK-positive non-small cell lung cancer (NSCLC).To compare ensartinib crizotinib among advanced NSCLC who had not received prior treatment ALK inhibitor.This open-label, multicenter, randomized, phase 3 trial conducted in 120 centers 21 countries enrolled 290 between July 25, 2016, November 12, 2018. Eligible were 18 years age or older advanced,...
Abstract Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of receptor tyrosine kinase. ARROW ( NCT03037385 , ongoing) was designed to evaluate pralsetinib efficacy and safety patients with advanced -altered solid tumors. Twenty-nine 12 different fusion–positive tumor types, excluding non-small-cell lung cancer thyroid cancer, who had previously received or were not candidates for standard therapies, enrolled. The most common fusion partners 23...
The CHOICE-01 study investigated the efficacy and safety of toripalimab in combination with chemotherapy as a first-line treatment for advanced non-small-cell lung cancer (NSCLC).Patients (N = 465) treatment-naive, NSCLC without EGFR/ALK mutations were randomly assigned 2:1 to receive 240 mg (n 309) or placebo 156) once every 3 weeks 4-6 cycles, followed by maintenance plus standard care. Stratification factors included programmed death ligand-1 expression status, histology, smoking status....
IntroductionEntrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001, STARTRK-1, and STARTRK-2 trials presented, with substantially longer follow-up, more patients, first description median overall survival (OS). exploratory in NSCLC central nervous system (CNS)–only progression post-crizotinib reported.MethodsAdults fusion–positive, locally advanced or metastatic who received at least one...
LBA9000 Background: EGFR TKIs are standard 1L therapy for metastatic NSCLC with sensitizing mutations; however, most patients (pts) ultimately experience PD. We report the protocol-specified final analysis (FA) from randomized, double-blind, phase 3 KEYNOTE-789 study of pemetrexed (pem) and platinum-based chemotherapy (chemo) or without pembrolizumab (pembro) as subsequent pts TKI-resistant, EGFR-mutant, nonsquamous (NCT03515837). Methods: Adults histologically cytologically confirmed stage...
8508 Background: Ivonescimab (AK112/SMT112) is a anti-PD-1/VEGF bispecific antibody. Previous phase I/II clinical studies have shown potential efficacy of ivonescimab in NSCLC patients with EGFR mutations who had failed prior EGFR-TKIs therapies. This 3 study aimed to evaluate and confirm the safety combined chemotherapy versus alone this population. Methods: Patients were randomized 1:1 receive (20 mg/kg) plus pemetrexed (500 mg/m 2 ) carboplatin (AUC 5) or placebo once every weeks for four...
Purpose: Leptomeningeal metastasis (LM) is a detrimental complication of non-small cell lung cancer (NSCLC) and associated with poor prognosis. However, the underlying mechanisms process are still poorly understood.Experimental Design: We performed next-generation panel sequencing primary tumor tissue, cerebrospinal fluid (CSF), matched normal controls from epidermal growth factor receptor (EGFR) mutation-positive NSCLC patients LM.Results: The status EGFR-activating mutations was highly...
IntroductionLorlatinib was found to have activity in ALK-positive NSCLC a global phase 1 and 2 study. We report an ongoing study Chinese patients with advanced or metastatic NSCLC.MethodsOpen-label, dual-cohort (NCT03909971); had progressive disease after ALK tyrosine kinase inhibitor treatment (cohort 1: previous crizotinib; cohort 2: one other than crizotinib [±prior crizotinib]), more equal unirradiated extracranial target lesion, Eastern Cooperative Oncology Group performance status of 0...
NTRK fusions result in constitutively active oncogenic TRK proteins responsible for ∼ 0.2 % of non-small cell lung cancer (NSCLC) cases. Approximately 40 patients with advanced NSCLC develop CNS metastases; therefore, treatments intracranial (IC) efficacy are needed. In an integrated analysis three phase I/II studies (ALKA-372-001: EudraCT 2012-000148-88; STARTRK-1: NCT02097810; STARTRK-2: NCT02568267), entrectinib, a potent, CNS-active, inhibitor, demonstrated fusion-positive (fp)...
IntroductionBy implementing dynamic circulating tumor DNA (ctDNA) analysis, we explored the impact of TP53 mutations on evolution and resistance mechanisms to ensartinib in patients with ALK-positive NSCLC.MethodsIn a multicenter phase 2 trial, NSCLC who progressed crizotinib were treated ensartinib. Blood samples for ctDNA analysis collected at baseline, cycle 3 day 1, progression disease (PD) analyzed 212-gene panel.ResultsA total 440 from 168 patients. Baseline (20.2%) significantly...
IntroductionRezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor (TKI) targeting both EGFR-sensitizing mutations and T790M mutation. This study aimed to evaluate the efficacy safety of rezivertinib in patients with locally advanced or metastatic/recurrent T790M-mutated NSCLC.MethodsPatients NSCLC confirmed mutation who progressed after first-/second-generation TKI therapy primary were enrolled. Patients received at 180 mg orally once daily until disease...
Limertinib (ASK120067) is a newly developed third-generation EGFR tyrosine kinase inhibitor targeting both sensitizing and Thr790Met (T790M) mutations. This study aimed to evaluate the efficacy safety of limertinib in patients with locally advanced or metastatic T790M-mutated NSCLC.This single-arm, open-label, phase 2b conducted at 62 hospitals across People's Republic China. Patients NSCLC centrally confirmed T790M mutations tumor tissue blood plasma who progressed after first-...
Objectives: Accumulating evidence has illustrated greater benefit of immunotherapy in tumors with high tumor mutation burden (TMB), whereas its impact on targeted therapy or chemotherapy is undefined. Herein, we evaluated TMB outside immuno-oncology epidermal growth factor receptor (EGFR)-mutant patients and EGFR/ALK wild-type cohorts. Methods: In this retrospective study, correlated response rate progression-free survival (PFS) who received EGFR-tyrosine kinase inhibitors (TKIs)...